Efforts toward oral bioavailability in factor VIIa inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 16, Issue 14, 2006, Pages 3829-3832

  Vijaykumar, Dange ^a   Rai, Roopa ^a   Shaghafi, Michael ^a   Ton, Tony ^a   Torkelson, Steve ^a   Leahy, Ellen M ^a   Riggs, Jennifer R ^a   Hu, Huiyong ^a   Sprengeler, Paul A ^a   Shrader, William D ^a   O'Bryan, Colin ^a   Cabuslay, Ronnell ^a   Sanford, Ellen ^a   Gjerstadt, Erik ^a   Liu, Liang ^a   Sukbuntherng, Juthamas ^a   Young, Wendy B ^a  

^a CELERA   (United States)

Author keywords

Factor VIIa inhibitor; Oral bioavailability; Parenteral lead; Polar surface area; Selectivity; Serine protease

Indexed keywords

BLOOD CLOTTING FACTOR 7A INHIBITOR;

ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG POTENCY; DRUG SYNTHESIS; MALE; NONHUMAN; PHYSICAL CHEMISTRY; RAT; STRUCTURE ACTIVITY RELATION;

ADMINISTRATION, ORAL; ANIMALS; ANTICOAGULANTS; BIOLOGICAL AVAILABILITY; FACTOR VIIA; RATS; STRUCTURE-ACTIVITY RELATIONSHIP; THROMBIN; THROMBOSIS;

EID: 33746567313     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2006.04.018     Document Type: Article

References (21)

1. Frederick R., Pochet L., Charlier C., and Masereel B. Curr. Med. Chem. 12 (2005) 397
2. Olivero A.G., Eigenbrot C., Goldsmith R., Robarge K., Artis D.R., Flygare J., Rawson T., Sutherlin D.P., Kadkhodayan S., Beresini M., Elliott L.O., DeGuzman G.G., Banner D.W., Ultsch M., Marzec U., Hanson S.R., Refino C., Bunting S., and Kirchhofer D. J. Biol. Chem. 280 (2005) 9160
3. Parlow J.J., Case B.L., Dice T.A., Fenton R.L., Hayes M.J., Jones D.E., Neumann W.L., Wood R.S., Lachance R.M., Girard T.J., Nicholson N.S., Clare M., Stegeman R.A., Stevens A.M., Stallings W.C., Kurumbail R.G., and South M.S. J. Med. Chem. 46 (2003) 4050
4. Young W.B., Kolesnikov A., Rai R., Sprengeler P.A., Leahy E.M., Shrader W.D., Sangalang J., Burgess-Henry J., Spencer J., Elrod K., and Cregar L. Bioorg. Med. Chem. Lett. 11 (2001) 2253
5. Kolesnikov, A.; Rai, R.; Young, W. B.; Torkelson, S.; Shrader, W. D.; Leahy, E. M.; Katz, B. A.; Sprengeler, P. A.; Liu, L.; Mordenti, J.; Gjerstad, E.; Janc, J. Abstracts of Papers, 229th ACS National Meeting, San Diego, CA, United States, March 13-17, 2005; MEDI-250.
6. Shrader, W. D.; Costerison, J.; Hendrix, J.; Hu, H.; Kolesnikov, A.; Kumar, V.; Leahy, E.; Rai, R.; Shaghafi, M.; Ton, T.; Torkelson, S.; Wesson, K.; Young, W. B.; Katz, B. A.; Sprengeler, P. A.; Yu, C.; Cabuslay, R.; Gjerstad, E.; Janc, J.; Sanford, E. Abstracts of Papers, 229th ACS National Meeting, San Diego, CA, United States, March 13-17, 2005; MEDI-251.
7. Young W.B., Mordenti J., Torkelson S., Shrader W.D., Kolesnikov A., Rai R., Liu L., Hu H., Leahy E.M., Green M.J., Sprengeler P.A., Katz B., Janc J.W., Marzec U.M., and Hanson S.R. Bioorg. Med. Chem. Lett. 16 (2006) 2037
8. Lipinski C.A., Lombardo F., Dominy B.W., and Feeney P.J. Adv. Drug Delivery Rev. (Netherlands) 46 (2001) 3
9. m (25 μM).
10. Bajaj S.P., and Joist J.H. Semin. Thromb. Hemost. 25 (1999) 407
11. Eriksson U.G., Bredberg U., Hoffmann K., Thuresson A., Gabrielsson M., Ericsson H., Ahnoff M., Gislén K., Fager G., and Gustafsson D. Drug Metab. Dispos. 31 (2003) 294
12. Katz B.A., Elrod K., Luong C., Rice M.J., Mackman R.L., Sprengeler P.A., Spencer J., Hataye J., Janc J., Link J., Litvak J., Rai R., Rice K., Sideris S., Verner E., and Young W. J. Mol. Biol. 307 (2001) 1451
13. Shrader W.D., Kolesnikov A., Burgess-Henry J., Rai R., Hu H., Torkelson S., Young W.B., Sprengeler P.A., Yu C., Katz B., Cabuslay R., Gjerstad E., and Janc J. Bioorg. Med. Chem. Lett. 16 (2006) 1596
14. Kolesnikov, A.; Rai, R.; Young, W. B.; Torkelson, S.; Shrader, W. D.; Leahy, E. M.; Katz, B. A.; Sprengeler, P.A.; Liu, L.; Mordenti, J.; Gjerstad, E.; Janc, J. Abstracts of Papers, 229th ACS National Meeting, San Diego, CA, United States, March 13-17, 2005; MEDI-250.
15. Riggs J.R., Kolesnikov A., Hendrix J., Young W.B., Shrader W.D., Vijaykumar D., Stephens R., Liu L., Pan L., Mordenti J., Green M.J., and Sukbuntherng J. Bioorg. Med. Chem. Lett. 16 (2006) 2224
16. iv,jv. Prodrug conversion was calculated by dividing the dose-normalized AUC of the parent after iv prodrug administration by the AUC of the parent after iv parent administration.
17. Liang L., Yun L., Christopher H., Lisa B., Young W., Doris G., Joyce M., and Juthamas S. Drug Metab. Rev. 37 Suppl. 2 (2005) 379
18. Hofslokken N.U., and Skattebol J. Acta Chem. Scand. 53 (1999) 258
19. Ishiyama T., Murata M., and Miyaura N. J. Org. Chem. 60 (1995) 7508
20. Roth G.J., Liepold B., Müller S.G., and Bestmann H.J. Synthesis 1 (2004) 59
21. Mackman R.L., Hui H.C., Breitenbucher J.G., Katz B.A., Luong C., Martelli A., McGee D., Radika K., Sendzik M., Spencer J.R., Sprengeler P.A., Tario J., Verner E., and Wang J. Bioorg. Med. Chem. Lett. 12 (2002) 2019